Lumida
/ETON
⌘K
Eton Pharmaceuticals Inc

Eton Pharmaceuticals Inc

ETON
$57.08USD-1.38%-0.80 today

MARKET CAP

1.6B

P/E (TTM)

FWD P/E

DAY RANGE

$56 – $60

52W RANGE

$14
$66

AI Summary

Stalk
Buy NowMedium

ETON has pulled back into the confluence of its rising 9 and 20 EMAs near prior support, where a Bearish Exhaustion inflection signals seller fatigue and increases the probability of a reversal bounce. The medium-term uptrend remains intact with higher highs and lows supported by the 50 DMA, while RSI retracement into near-oversold territory aligns short-term timing for a rebound. We recommend initiating long positions now at the EMA support zone with focus on price acceptance above this level.

  • Q2 revenue climbed 99% YoY to $37.6M, driving record top-line growth.
  • Management upped full-year 2026 revenue forecast from $120M to >$145M.
  • Negative earnings yield and weak book-to-price raise valuation red flags.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$21.8M$21.3M$31.6M$39.0M$80.0M
YoY %+55879.5%-2.7%+48.9%+23.3%+104.9%
P / Sales5.0x3.4x3.7x8.8x5.7x
EV / Sales4.7x3.2x3.6x9.8x6.2x
Gross Profit, Adj.$19.0M$14.3M$21.1M$23.4M$42.7M
YoY %+4887.2%-24.7%+47.1%+11.2%+82.6%
Margin %87.1%67.4%66.6%60.0%53.5%
EV / Gross Profit5.4x4.8x5.3x16.3x11.6x
EBITDA, Adj.$-1.0M$-6.5M$-291,000$-1.5M$3.2M
YoY %+96.1%-527.9%+95.5%-398.6%+320.5%
Margin %-4.7%-30.5%-0.9%-3.7%4.0%
EV / EBITDA-100.3x-10.5x-386.9x-263.0x154.7x
EBIT$-1.5M$-8.3M$-1.2M$-2.6M$-844,000
YoY %+94.5%-452.5%+85.6%-117.9%+67.5%
Margin %-6.8%-38.9%-3.8%-6.7%-1.1%
EV / EBIT-69.3x-8.3x-94.5x-147.0x-586.5x
Net Income$-2.0M$-9.0M$-936,000$-3.8M$-4.6M
YoY %+93.0%-361.4%+89.6%-308.4%-20.4%
Net Margin-9.0%-42.4%-3.0%-9.8%-5.8%
EPS (GAAP)-$0.08-$0.36-$0.04-$0.15-$0.17
YoY %+94.0%-350.0%+88.9%-275.0%-13.3%